S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Investors Look to Capitalize on the Budding Green Revolution (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Investors Look to Capitalize on the Budding Green Revolution (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Investors Look to Capitalize on the Budding Green Revolution (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
Investors Look to Capitalize on the Budding Green Revolution (Ad)
The How and Why of Investing in Gold Stocks
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
Wall Street roars after inflation cools more than expected
Rhine River could fall below critical mark, risking industry
Investors Look to Capitalize on the Budding Green Revolution (Ad)
NASDAQ:NKTR

Nektar Therapeutics - NKTR Price Target & Analyst Ratings

$4.85
+0.14 (+2.97%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.65
$4.87
50-Day Range
$3.17
$4.88
52-Week Range
$3.02
$19.37
Volume
1.64 million shs
Average Volume
3.23 million shs
Market Capitalization
$908.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

Nektar Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 13 Analyst Ratings

Consensus Analyst Price Target

$13.17
171.48% Upside
High Prediction$54.00
Average Prediction$13.17
Low Prediction$3.00
TypeCurrent
8/11/21 to 8/11/22
1 Month Ago
7/12/21 to 7/12/22
3 Months Ago
5/13/21 to 5/13/22
1 Year Ago
8/11/20 to 8/11/21
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.17$13.17$13.17$23.75
Predicted Upside171.48% Upside98.94% Upside98.94% Upside27.41% Upside
Get Nektar Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.


NKTR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NKTR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nektar Therapeutics Stock vs. The Competition

TypeNektar TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.71
2.50
Consensus RatingHoldBuyHold
Predicted Upside171.48% Upside734.50% Upside16.33% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
626
72.62%
Underperform Votes
236
27.38%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
68.68%
Avg. Underperform Votes
383
31.32%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/8/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
4/20/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
4/18/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$3.00-27.36%
4/18/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Perform$7.00 ➝ $6.00-2.60%
4/18/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$8.00 ➝ $6.00-2.60%
3/16/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$25.00 ➝ $6.00+33.93%
3/14/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$35.00 ➝ $8.00+87.35%
3/14/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$24.00 ➝ $5.00+24.07%
3/14/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
3/14/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hsieh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/14/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$18.00 ➝ $6.00+19.28%
11/8/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$20.00+48.70%
6/10/2020Cfra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Sell
5/12/2020HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Debjit Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$32.00 ➝ $26.00+14.69%
3/4/2020Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$30.00+54.40%
2/28/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tyler Van Buren
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$35.00+68.19%
11/7/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tyler Van Buren
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight$50.00 ➝ $35.00+87.17%
8/11/2019Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$37.00+76.86%
(Data available from 8/11/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NKTR Price Target - Frequently Asked Questions

What is Nektar Therapeutics's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Nektar Therapeutics stock is Hold based on the current 3 sell ratings, 7 hold ratings and 3 buy ratings for NKTR. The average twelve-month price prediction for Nektar Therapeutics is $13.17 with a high price target of $54.00 and a low price target of $3.00. Learn more on NKTR's analyst rating history.

Do Wall Street analysts like Nektar Therapeutics more than its competitors?

Analysts like Nektar Therapeutics less than other Medical companies. The consensus rating for Nektar Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how NKTR compares to other companies.

Do MarketBeat users like Nektar Therapeutics more than its competitors?

MarketBeat users like Nektar Therapeutics more than other Medical companies. 72.54% of MarketBeat users gave Nektar Therapeutics an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is Nektar Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Nektar Therapeutics's stock had 1 downgrade by analysts.

Does Nektar Therapeutics's stock price have much upside?

According to analysts, Nektar Therapeutics's stock has a predicted upside of 98.94% based on their 12-month price targets.

What analysts cover Nektar Therapeutics?

Nektar Therapeutics has been rated by JPMorgan Chase & Co. in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:NKTR) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.